Galecto (NASDAQ:GLTO) Posts Earnings Results

Galecto (NASDAQ:GLTO) issued its quarterly earnings data on Thursday. The company reported ($2.36) EPS for the quarter, Zacks reports.

Galecto Price Performance

GLTO stock traded down $0.12 during midday trading on Thursday, hitting $5.82. The company’s stock had a trading volume of 20,313 shares, compared to its average volume of 834,596. Galecto has a twelve month low of $2.01 and a twelve month high of $31.70. The company’s fifty day moving average price is $6.06 and its 200 day moving average price is $4.23. The stock has a market capitalization of $7.68 million, a P/E ratio of -0.44 and a beta of 1.45.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on GLTO. Weiss Ratings restated a “sell (d-)” rating on shares of Galecto in a report on Tuesday, October 14th. Wall Street Zen upgraded shares of Galecto to a “sell” rating in a report on Saturday, October 25th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Galecto Company Profile

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.